COMMUNIQUÉS West-GlobeNewswire

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
16/10/2025
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International Conference Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher [...]
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
16/10/2025
CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it [...]
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
16/10/2025
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc [...]
Belite Bio to Participate in the 2025 Maxim Growth Summit
16/10/2025
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal [...]
Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
16/10/2025
Clinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering precision treatment and better patient outcomes TORONTO, Oct. 16, 2025 (GLOBE [...]
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
16/10/2025
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF and APRIL validated [...]
PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics
16/10/2025
MINNEAPOLIS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW) and an emerging biomedical device company focused on the [...]
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
16/10/2025
Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious [...]
Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland
16/10/2025
FORT MILL, S.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company and a leading developer of innovative solutions for cardiac procedures, is pleased to [...]
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
16/10/2025
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16/10/2025
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observed Multi-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 ( [...]
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
16/10/2025
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related [...]
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
16/10/2025
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors - Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
16/10/2025
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an [...]
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
16/10/2025
First U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System Company Completes the Recruitment of its Commercial Leadership [...]
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
16/10/2025
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc [...]
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
16/10/2025
Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. ( [...]
Cannabix Technologies Delivers BreathLogix Alcohol Screening Device to Oilfield Transportation Services Company
16/10/2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is [...]
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
16/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]

Pages